We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Aviva Plc | LSE:AV. | London | Ordinary Share | GB00BPQY8M80 | ORD 32 17/19P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.60 | 0.77% | 472.00 | 472.10 | 472.30 | 474.50 | 468.60 | 470.00 | 3,223,825 | 16:35:01 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Insurance Carriers, Nec | 41.43B | 1.09B | 0.3962 | 11.92 | 12.93B |
From May 2019 to May 2024
TIDMAPH TIDMAV.
RNS Number : 1266D
Alliance Pharma PLC
24 April 2017
For immediate release 24 April 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Changes to interests of a significant shareholder
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM rule 17, the following details are now notified:
(a) Identity of the significant shareholder: Aviva plc and its subsidiaries
(b) Date of disclosure: 21 April 2017
(c) Date of relevant change: 20 April 2017
(d) Price, amount and class: 12,147,669 ordinary shares of 1p each; price not disclosed
(e) Nature of transaction: sale of shares
(f) Nature and extent of significant shareholder's interest: direct and indirect interests
(g) Resultant shareholding: 4.98% (direct) and 0.16% (indirect)
In compliance with DTR5, a copy of the notification received from this investor is appended.
For further information:
Hot Features
Premium
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
-----------------------------------------------
1. Identity of the issuer or Alliance Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached:
--------------------------------------------------------------- -------------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------------- ---------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------- ---------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------- ---------------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------- ---------------------------------------
Other (please
specify):
----------------------------------------------------------- ------ ---------------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
------------------------------------------------------------- ---------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.): Available on request 18,450*
Chase (GA Group) Nominees
Limited 23,512,546*
*denotes direct interest
Chase Nominees Limited 778,280
------------------------------------------------------------- ---------------------------------------------
5. Date of the transaction 20 April 2017
and date on
which the threshold is
crossed or
reached:
------------------------------------------------------------- ---------------------------------------------
6. Date on which issuer 21 April 2017
notified:
------------------------------------------------------------- ---------------------------------------------
7. Threshold(s) that is/are 7% to 4% Change at Direct
crossed or Interest Level (Box 8A & Box
reached: 8A&B)
------------------------------------------------------------- ---------------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
----------------- ------------------------------- ----------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights
Shares Voting
Rights
----------------- ----------------- ------------ ------------ ----------------------- -------------------
Direct Direct Indirect Direct Indirect
----------------- ----------------- ------------ ------------ ----------- ---------- ------- ----------
Ordinary
Shares
GB0031030819 36,456,945* 36,456,945* 24,309,276 23,530,996 778,280 4.98% 0.16%
----------------- ------------ ------------ ----------- ---------- ------- ----------
* Includes Right to Recall Loaned Shares (50,000)
--------------------------------------------------------------------------------------------------------------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument Period may be
acquired if
the
instrument
is
exercised/
converted.
----------------- ----------------- -------------------------- ----------------------- -------------------
50,000*
RIGHT TO RECALL
LOANED SHARES N/A N/A *Direct Interest 0.01%
----------------- ----------------- -------------------------- ----------------------- -------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights
period refers to
------------------ --------- ----------- ------------ ------------------- ----------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- -------- ------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
24,359,276 5.15%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
---------------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited and Friends Provident
International Limited, with the following chain of controlled
undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Friends Provident International Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Friends Provident International Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
Proxy Voting:
---------------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
-------------------------------------------------- -----------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
-------------------------------------------------- -----------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
-------------------------------------------------- -----------------------------------
13. Additional information: Figures are based on a total
number of voting rights of
472,795,052, as per the Company's
'Application for admission'
announcement of 31(st) March
2017.
-------------------------------------------------- -----------------------------------
14. Contact name: Neil Whittaker, Aviva plc
-------------------------------------------------- -----------------------------------
15. Contact telephone number: 01603 684420
-------------------------------------------------- -----------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLPGURPCUPMGUC
(END) Dow Jones Newswires
April 24, 2017 06:33 ET (10:33 GMT)
1 Year Aviva Chart |
1 Month Aviva Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
